PMN ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform co…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... ProMIS Neurosciences reports strong safety profile and target engagement in PRECISE-AD trial, with cash runway through 2027. | ||
 Promis Neurosciences Q2 Earnings Call Highlights Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early Alzheimer’s disease. President and Chief Executive Officer Neil Warma said the company is using i | ||
 Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data Promis Neurosciences (NASDAQ:PMN) reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer’s disease and early Alzheimer’s | ||
 ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results ProMIS Neurosciences Inc. (NASDAQ:PMN) shares gained 13% on Tuesday after the company released encouraging six-month interim safety and biomarker data from its ongoing PRECISE-AD Phase 1b study evaluating PMN310 in patients with Alzheimer’s disease. | ||